Brief: Nanogroup Unit Updates On Test Results For Ovarian Cancer Drug Candidate PolEpi

Nanogroup SA

15/02/2022 13:50

Feb 15 (Reuters) - Nanogroup SA  NNG.WA :
    * SAYS UNIT NANOVELOS UPDATES ON TEST RESULTS FOR OVARIAN
CANCER
DRUG CANDIDATE POLEPI
    * SAYS TEST SHOWS MAX TOLERATED DOSE OF POLEPI IS
SIGNIFICANTLY
HIGHER THAN FOR PURE DRUG AGAINST WHICH POLEPI WAS COMPARED
    * SAYS TEST WAS CONDUCTED ON FEMALE MICE
    * SAYS RESULTS ENABLE TESTING PARTY TO MOVE ONTO NEXT STAGE
OF
POLEPI TESTS ON MICE

Source text for Eikon:  ID:nEM8hVM1Ca 
Further company coverage:  NNG.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))